Background Clinical situations occur where expedient assessment of the anticoagulant
activity of the direct factor Xa (FXa) inhibitors is required. Although quantitative anti‐FXa …

Introduction Apixaban is an oral direct factor Xa inhibitor developed for the prophylaxis and
treatment of thromboembolic disorders. Laboratory monitoring is not necessary, but the …

The introduction of oral direct anti-Xa anticoagulants apixaban and rivaroxaban has
significantly impacted the treatment and prevention of thromboembolic disease. Clinical …

Rivaroxaban and apixaban are both small molecules that reversibly inhibit factor Xa.
Compared with rivaroxaban, apixaban has minimal effects on the prothrombin time and …

Background The determination of rivaroxaban and apixaban from serum samples of patients
may be beneficial in specific clinical situations when additional blood sampling for plasma …

Background: There is no established method for monitoring the anticoagulant effects of
apixaban and rivaroxaban. Linear correlation between serum levels and anti-Xa activity has …

Introduction: Rivaroxaban is an oral direct factor Xa inhibitor developed for prophylaxis and
treatment of thromboembolic disorders. Laboratory monitoring is not necessary but the dose …

Background The anticoagulant actions of oral direct factor Xa (FXa) inhibitors can be
inferred from their observed plasma concentrations; however, the steady-state …

Apixaban and other factor Xa (FXa) inhibitors are in late-stage clinical development for
prevention and treatment of thromboembolic diseases. Although routine monitoring will not …

Although there is no need for routine coagulation monitoring with rivaroxaban–an oral, direct
factor Xa inhibitor–a haemostasis assay might be valuable to measure its pharmacodynamic …